Potential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics
Abstract Background Esophageal squamous cell carcinoma (ESCC), the most common type of esophageal cancer, characterized by low five-year survival rate, and concurrent chemoradiotherapy (CCRT) has been proposed to treat ESCC, while potential biomarkers for prognostic monitoring after optimized CCRT r...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13866-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850023368236990464 |
|---|---|
| author | Jie Yang Yunyun Zhu Yijian Zhou Jiaying Zhang Yuxuan Wei Yongpan Liu Bo Zhang Jialing Xie Xiaolu An Xianhua Qi Yuting Yue Lijia Zhang Xiajun Zhang Zhichao Fu Kuancan Liu |
| author_facet | Jie Yang Yunyun Zhu Yijian Zhou Jiaying Zhang Yuxuan Wei Yongpan Liu Bo Zhang Jialing Xie Xiaolu An Xianhua Qi Yuting Yue Lijia Zhang Xiajun Zhang Zhichao Fu Kuancan Liu |
| author_sort | Jie Yang |
| collection | DOAJ |
| description | Abstract Background Esophageal squamous cell carcinoma (ESCC), the most common type of esophageal cancer, characterized by low five-year survival rate, and concurrent chemoradiotherapy (CCRT) has been proposed to treat ESCC, while potential biomarkers for prognostic monitoring after optimized CCRT remains unknown. Methods Serum samples from 45 patients with ESCC were collected and categorized into three groups: Control (pre-CCRT), CCRT (during CCRT), and CCRT-1 M (one-month post-CCRT). The therapeutic effect was evaluated using CT imaging and established evaluation criteria. Untargeted metabolomic analysis was performed on the serum samples to identify differential metabolites caused by CCRT treatment, assessing their potential for prognostic monitoring. Results CCRT had significant therapeutic efficacy in patients with ESCC, as indicated by CT imaging and RECIST 1.1 solid tumor evaluation criteria. Notably, several metabolic markers were identified through non-targeted metabolomic analysis, highlighting changes following CCRT treatment. These differential metabolites are involved in the dysregulation of phenylalanine, tyrosine, and tryptophan biosynthesis, as well as histidine, arginine, and proline metabolism, and glycine, serine, and threonine metabolism, suggesting a reduction in glucose metabolism in patients with ESCC after CCRT. Additionally, ROC analysis indicated that the AUC of these metabolites exceeded 0.661, underscoring their diagnostic value for assessing CCRT efficacy and their potential use in prognostic monitoring. Comparative metabolomic analysis identified L-phenylalanine and lysine as promising serum biomarkers for predicting therapeutic outcomes. Conclusions CCRT shows considerable therapeutic benefit in patients with ESCC, with observed reductions in glucose metabolism post-treatment. L-phenylalanine and lysine may serve as potential serum biomarkers to predict CCRT efficacy. |
| format | Article |
| id | doaj-art-19766718003c4cab95aefc3de90cee95 |
| institution | DOAJ |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-19766718003c4cab95aefc3de90cee952025-08-20T03:01:23ZengBMCBMC Cancer1471-24072025-03-0125111510.1186/s12885-025-13866-xPotential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomicsJie Yang0Yunyun Zhu1Yijian Zhou2Jiaying Zhang3Yuxuan Wei4Yongpan Liu5Bo Zhang6Jialing Xie7Xiaolu An8Xianhua Qi9Yuting Yue10Lijia Zhang11Xiajun Zhang12Zhichao Fu13Kuancan Liu14Central Laboratory, Danyang People’s Hospital of Jiangsu ProvinceDepartment of Radiotherapy, 900 Hospital of the Joint Logistics Team, (Dongfang Hospital, Xiamen University)Central Laboratory, School of Medicine, Xiang’an Hospital of Xiamen University, Xiamen UniversityCentral Laboratory, School of Medicine, Xiang’an Hospital of Xiamen University, Xiamen UniversityCentral Laboratory, School of Medicine, Xiang’an Hospital of Xiamen University, Xiamen UniversitySchool of Life Science, Xiamen UniversityCentral Laboratory, School of Medicine, Xiang’an Hospital of Xiamen University, Xiamen UniversityCentral Laboratory, School of Medicine, Xiang’an Hospital of Xiamen University, Xiamen UniversityCentral Laboratory, School of Medicine, Xiang’an Hospital of Xiamen University, Xiamen UniversityCentral Laboratory, School of Medicine, Xiang’an Hospital of Xiamen University, Xiamen UniversityCentral Laboratory, School of Medicine, Xiang’an Hospital of Xiamen University, Xiamen UniversityCentral Laboratory, School of Medicine, Xiang’an Hospital of Xiamen University, Xiamen UniversityCentral Laboratory, Danyang People’s Hospital of Jiangsu ProvinceDepartment of Radiotherapy, 900 Hospital of the Joint Logistics Team, (Dongfang Hospital, Xiamen University)Central Laboratory, School of Medicine, Xiang’an Hospital of Xiamen University, Xiamen UniversityAbstract Background Esophageal squamous cell carcinoma (ESCC), the most common type of esophageal cancer, characterized by low five-year survival rate, and concurrent chemoradiotherapy (CCRT) has been proposed to treat ESCC, while potential biomarkers for prognostic monitoring after optimized CCRT remains unknown. Methods Serum samples from 45 patients with ESCC were collected and categorized into three groups: Control (pre-CCRT), CCRT (during CCRT), and CCRT-1 M (one-month post-CCRT). The therapeutic effect was evaluated using CT imaging and established evaluation criteria. Untargeted metabolomic analysis was performed on the serum samples to identify differential metabolites caused by CCRT treatment, assessing their potential for prognostic monitoring. Results CCRT had significant therapeutic efficacy in patients with ESCC, as indicated by CT imaging and RECIST 1.1 solid tumor evaluation criteria. Notably, several metabolic markers were identified through non-targeted metabolomic analysis, highlighting changes following CCRT treatment. These differential metabolites are involved in the dysregulation of phenylalanine, tyrosine, and tryptophan biosynthesis, as well as histidine, arginine, and proline metabolism, and glycine, serine, and threonine metabolism, suggesting a reduction in glucose metabolism in patients with ESCC after CCRT. Additionally, ROC analysis indicated that the AUC of these metabolites exceeded 0.661, underscoring their diagnostic value for assessing CCRT efficacy and their potential use in prognostic monitoring. Comparative metabolomic analysis identified L-phenylalanine and lysine as promising serum biomarkers for predicting therapeutic outcomes. Conclusions CCRT shows considerable therapeutic benefit in patients with ESCC, with observed reductions in glucose metabolism post-treatment. L-phenylalanine and lysine may serve as potential serum biomarkers to predict CCRT efficacy.https://doi.org/10.1186/s12885-025-13866-xEsophageal squamous cell carcinomaMetabolomicsCCRTPrognosisBiomarkers |
| spellingShingle | Jie Yang Yunyun Zhu Yijian Zhou Jiaying Zhang Yuxuan Wei Yongpan Liu Bo Zhang Jialing Xie Xiaolu An Xianhua Qi Yuting Yue Lijia Zhang Xiajun Zhang Zhichao Fu Kuancan Liu Potential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics BMC Cancer Esophageal squamous cell carcinoma Metabolomics CCRT Prognosis Biomarkers |
| title | Potential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics |
| title_full | Potential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics |
| title_fullStr | Potential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics |
| title_full_unstemmed | Potential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics |
| title_short | Potential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics |
| title_sort | potential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics |
| topic | Esophageal squamous cell carcinoma Metabolomics CCRT Prognosis Biomarkers |
| url | https://doi.org/10.1186/s12885-025-13866-x |
| work_keys_str_mv | AT jieyang potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT yunyunzhu potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT yijianzhou potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT jiayingzhang potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT yuxuanwei potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT yongpanliu potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT bozhang potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT jialingxie potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT xiaoluan potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT xianhuaqi potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT yutingyue potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT lijiazhang potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT xiajunzhang potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT zhichaofu potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics AT kuancanliu potentialbiomarkersdevelopforpredictingtheprognosisofpatientswithesophagealsquamouscellcarcinomaafteroptimizedchemoradiotherapyusingserummetabolomics |